Bradley E. Enerson
27 works · 1,941 citations · h-index 14
Top works
- Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats
- Pathway analysis using random forests classification and regression
- Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain
- Expression of the monocarboxylate transporter MCT2 by rat brain glia
- Molecular Features, Regulation, and Function of Monocarboxylate Transporters: Implications for Drug Delivery
- Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues
- Expression of Large Amino Acid Transporter LAT1 in Rat Brain Endothelium
- The Rat Blood—Brain Barrier Transcriptome
- IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
- Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging
- Acute Drug-Induced Vascular Injury in Beagle Dogs: Pathology and Correlating Genomic Expression
- Nonclinical Safety Biomarkers of Drug-induced Vascular Injury
- Toxicity of Hydroxyurea in Rats and Dogs
- The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies
- The Role of eNOS Phosphorylation in Causing Drug-induced Vascular Injury
- Hemodynamic Correlates of Drug-induced Vascular Injury in the Rat Using High-frequency Ultrasound Imaging
- Effects of Modulating In Vivo Nitric Oxide Production on the Incidence and Severity of PDE4 Inhibitor–Induced Vascular Injury in Sprague-Dawley Rats
- Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
- Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging
- STAT3 degraders inhibit cellular activation, cytokine production, and Th17 development, resulting in inhibition of autoimmunity in the MOG-EAE model of CNS inflammation.